Gonadotropin Releasing Hormone Agonists and Antagonists + Bicalutamide + Pembrolizumab
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High Risk Prostate Carcinoma
Conditions
High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Trial Timeline
Apr 16, 2025 → Jun 1, 2028
NCT ID
NCT06528210About Gonadotropin Releasing Hormone Agonists and Antagonists + Bicalutamide + Pembrolizumab
Gonadotropin Releasing Hormone Agonists and Antagonists + Bicalutamide + Pembrolizumab is a phase 2 stage product being developed by Merck for High Risk Prostate Carcinoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06528210. Target conditions include High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06528210 | Phase 2 | Withdrawn |
Competing Products
20 competing products in High Risk Prostate Carcinoma